Anti-IL-22Ra reference antibody (ARGX-112) is used primarily in research and development for targeting the interleukin-22 receptor alpha (IL-22Ra), which plays a key role in inflammatory and autoimmune diseases. It serves as a critical tool in preclinical studies to block IL-22 signaling, helping evaluate therapeutic strategies for conditions such as psoriasis, inflammatory bowel disease, and other chronic inflammatory disorders. Due to its high specificity, it is also employed in assay development and as a reference standard in neutralization tests to compare the efficacy of novel anti-IL-22 pathway candidates. Its application supports the advancement of biologics aimed at modulating immune responses in tissue inflammation and repair.